Puleva Biotech, S.a.

N.v. Nutricia

Juan Miguel Rodríguez Gómez

Julio Boza Puerta

Jordi Xaus Pei

Jesús Jiménez López

Esther Antonia Jiménez Quintana

Jan Knol

Mónica Olivares Martín

Saleta Sierra Ávila

Rocio Martín Jiménez

Maria Luisa Marín Martínez

Odón Julían Sobrino Abuja

Susana Delgado Palacio

Rocio Martin

Virginia Martín Merino

Rocío Martin Jiménez

Leónides Fernández Álvarez

Irene Espinosa Martos

Antonio Maldonado Barragán

Francesc Blanch Martell

Celina Torre Lloveras

Leonides Fernández Álvarez

Federico Lara Villoslada

Rebeca Arroyo Rodríguez

The invention relates to a new strain of, products containing the new strain, the use thereof in and methods for the treatment and/or prevention of inflammation and/or infection in breast or udder tissue, particularly in a mammary gland of a human female. The inflammation and/or infection is preferably mastitis.

for the treatment of mastitis

The present invention relates to a novel approach to prevent or treat mastitis both in humans and animals through the use of mammal milk-derived microorganisms obtained from healthy hosts of the homologous species; to those new probiotic microorganisms obtained from milk able to reduce infectious mastitis and the method of screening used for their obtaining; to the use of these probiotic bacteria for the prophylaxis or treatment against mastitis and other diseases; and finally, to compositions comprising these compounds.

Mammalian milk microorganisms, compositions containing them and their use for the treatment of mastitis

The present invention relates to a novel process for the selection of new probiotic strains which comprises the following steps: a) selecting for non-pathogenic strains which are capable of surviving in breast milk and/or amniotic fluid, and b) selecting for non-pathogenic strains which are able to be transferred to breast milk and/or amniotic fluid after oral intake in healthy individuals without colonizing other internal organs except mucousas. The invention also provides newstrains, which are: CECT5711 (), CECT5713 (subsp.), CECT5714: (, formerly), CETC5715: (), and CECT5716: (); and refers to their use for the prophylaxis or treatment against digestive, infective, neuro-degenerative and immune related diseases such as allergies or inflammatory diseases.

Probiotic strains, a process for the selection of them, compositions thereof, and their use

Growing community of inventors

Colmenar Viejo-Madrid, Spain

Juan Miguel Rodríguez Gómez